FM regimen
WikiDoc Resources for FM regimen |
Articles |
---|
Most recent articles on FM regimen |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on FM regimen at Clinical Trials.gov Clinical Trials on FM regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on FM regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on FM regimen Discussion groups on FM regimen Patient Handouts on FM regimen Directions to Hospitals Treating FM regimen Risk calculators and risk factors for FM regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for FM regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: R-FM Regimen; Rituximab-Fludarabine-Mitoxantrone Regimen
Overview
FM regimen refers to a regimen consisting of rituximab, fludarabine and mitoxantrone used for the treatment of indolent non-Hodgkin's lymphoma.[1]
Regimen
RRituximab
FFludarabine
MMitoxantrone
Indications
References
- ↑ 1.0 1.1 Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A; et al. (2004). "Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma". J Clin Oncol. 22 (13): 2654–61. doi:10.1200/JCO.2004.07.170. PMID 15159414.